Analystreport

Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at Raymond James from $122.00 to $133.00. They now have a "strong-buy" rating on the

Blueprint Medicines Corporation  (BPMC) 
Last blueprint medicines corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: blueprintmedicines.com